Skip to main content
Access every election story that matters
Enjoy unlimited digital access
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
per week
for 24 weeks
// //

Dbv Technologies ADR NASDAQ: DBVT-Q

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 5.15
Day High 5.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.


Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.



A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Beyond Air(R) Announces CFO Transition
- GlobeNewswire - Fri Aug 20, 3:15PM CDT
GlobeNewswire - CMTX
Fri Aug 20, 3:15PM CDT
Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 4.73 +10.15% increase
on 08/17/21
Period Open:4.87
Price movement based on the high, low and last over the given period.
5.99 -13.02% decrease
on 08/31/21
+0.34 (+6.98%) increase
since 08/13/21
3-Month 4.66 +11.80% increase
on 08/04/21
Period Open:6.32
Price movement based on the high, low and last over the given period.
6.41 -18.72% decrease
on 06/16/21
-1.11 (-17.56%) decrease
since 06/15/21
52-Week 1.35 +285.93% increase
on 10/29/20
Period Open:1.96
Price movement based on the high, low and last over the given period.
7.38 -29.40% decrease
on 01/19/21
+3.25 (+165.82%) increase
since 09/15/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies